MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results -- Contact BFA Law

Core Insights - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, a treatment for inflammatory diseases [1][2][3] Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2] Recent Developments - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3] - Following the announcement, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3] Legal Context - Bleichmar Fonti & Auld LLP is investigating the situation and encourages investors to seek additional information regarding potential legal options [1][4]